Cargando…

Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia

OBJECTIVE: This study investigated the types and significance of mutant genes in children with acute lymphoblastic leukemia (ALL). METHODS: The gene sequencing data of 89 ALL children were retrospectively analyzed. Log-rank test was used to analyze the effect of different numbers of mutant genes on...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu, Nuriding, Hailiqiguli, Zhao, Li, Wang, Xuemei, Yue, Yingbin, Song, Yue, Yan, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398850/
https://www.ncbi.nlm.nih.gov/pubmed/36017149
http://dx.doi.org/10.1155/2022/7904293
_version_ 1784772407068721152
author Liu, Yu
Nuriding, Hailiqiguli
Zhao, Li
Wang, Xuemei
Yue, Yingbin
Song, Yue
Yan, Mei
author_facet Liu, Yu
Nuriding, Hailiqiguli
Zhao, Li
Wang, Xuemei
Yue, Yingbin
Song, Yue
Yan, Mei
author_sort Liu, Yu
collection PubMed
description OBJECTIVE: This study investigated the types and significance of mutant genes in children with acute lymphoblastic leukemia (ALL). METHODS: The gene sequencing data of 89 ALL children were retrospectively analyzed. Log-rank test was used to analyze the effect of different numbers of mutant genes on the clinical characteristics of the patients and disease. RESULTS: Known gene mutations were detected in 64% (57/89) of the children, including one gene mutation in 31% and two or more gene mutations in 33% of the patients. Gene sequencing showed that most mutations occurred in KRAS (17%), NRAS (15%), FLT3 (7%), TP53 (7%), and PTPN11 (7%), and functional clustering analysis showed that most were signaling pathway genes (50%). In the overall cohort, no association was found between clinical characteristics and gene mutation. The children were then classified into three groups: group A (no gene mutation), group B (one gene mutation), and group C (two or more gene mutations). Correlation analysis showed that group A had significantly more children with medium risk ALL (P = 0.037), and group C had markedly more children with high risk ALL (P = 0.001). Further analysis showed that children with mutant genes took significantly more time to enter the maintenance phase than children without mutations. CONCLUSION: Children with ALL had a high gene mutation rate, especially in KRAS and NRAS genes, and the mutant genes were mainly signal pathway-related. The gene mutations were significantly correlated with clinical phenotype and the time taken to enter the maintenance phase.
format Online
Article
Text
id pubmed-9398850
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93988502022-08-24 Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia Liu, Yu Nuriding, Hailiqiguli Zhao, Li Wang, Xuemei Yue, Yingbin Song, Yue Yan, Mei Comput Math Methods Med Research Article OBJECTIVE: This study investigated the types and significance of mutant genes in children with acute lymphoblastic leukemia (ALL). METHODS: The gene sequencing data of 89 ALL children were retrospectively analyzed. Log-rank test was used to analyze the effect of different numbers of mutant genes on the clinical characteristics of the patients and disease. RESULTS: Known gene mutations were detected in 64% (57/89) of the children, including one gene mutation in 31% and two or more gene mutations in 33% of the patients. Gene sequencing showed that most mutations occurred in KRAS (17%), NRAS (15%), FLT3 (7%), TP53 (7%), and PTPN11 (7%), and functional clustering analysis showed that most were signaling pathway genes (50%). In the overall cohort, no association was found between clinical characteristics and gene mutation. The children were then classified into three groups: group A (no gene mutation), group B (one gene mutation), and group C (two or more gene mutations). Correlation analysis showed that group A had significantly more children with medium risk ALL (P = 0.037), and group C had markedly more children with high risk ALL (P = 0.001). Further analysis showed that children with mutant genes took significantly more time to enter the maintenance phase than children without mutations. CONCLUSION: Children with ALL had a high gene mutation rate, especially in KRAS and NRAS genes, and the mutant genes were mainly signal pathway-related. The gene mutations were significantly correlated with clinical phenotype and the time taken to enter the maintenance phase. Hindawi 2022-08-16 /pmc/articles/PMC9398850/ /pubmed/36017149 http://dx.doi.org/10.1155/2022/7904293 Text en Copyright © 2022 Yu Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Yu
Nuriding, Hailiqiguli
Zhao, Li
Wang, Xuemei
Yue, Yingbin
Song, Yue
Yan, Mei
Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title_full Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title_fullStr Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title_full_unstemmed Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title_short Genomic and Clinical Analysis of Children with Acute Lymphoblastic Leukemia
title_sort genomic and clinical analysis of children with acute lymphoblastic leukemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398850/
https://www.ncbi.nlm.nih.gov/pubmed/36017149
http://dx.doi.org/10.1155/2022/7904293
work_keys_str_mv AT liuyu genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT nuridinghailiqiguli genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT zhaoli genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT wangxuemei genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT yueyingbin genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT songyue genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia
AT yanmei genomicandclinicalanalysisofchildrenwithacutelymphoblasticleukemia